| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471639A1 Novel alkyl/aryl hydroxy or keto thiepines. |
| 07/31/2003 | CA2471383A1 Amido macrolides |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | CA2470185A1 Use of alkylphosphocholines in the prevention of protozoal diseases |
| 07/31/2003 | CA2469685A1 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 07/31/2003 | CA2469665A1 Infection-resistant medical devices |
| 07/31/2003 | CA2466266A1 Novel substituted alkane compounds and uses thereof |
| 07/31/2003 | CA2441796A1 Solid orally-dispersible pharmaceutical formulation |
| 07/30/2003 | EP1331223A1 Method of treating sepsis |
| 07/30/2003 | EP1331010A1 Preventives and remedies for central nervous system diseases |
| 07/30/2003 | EP1331004A2 Aminotetralin Derivative for the Therapy of Cardiovascular Diseases |
| 07/30/2003 | EP1331003A1 Extended release formulation containing venlafaxine |
| 07/30/2003 | EP1331001A1 Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications |
| 07/30/2003 | EP1330999A1 Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative |
| 07/30/2003 | EP1330562A1 Method for the production of low defect density silicon |
| 07/30/2003 | EP1330548A2 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 07/30/2003 | EP1330543A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330520A2 Therapeutic oligonucleotides of reduced toxicity |
| 07/30/2003 | EP1330515A1 Methods of agonizing and antagonizing fabk |
| 07/30/2003 | EP1330470A1 Glutathione conjugates with distamycin derivatives having antitumor activity |
| 07/30/2003 | EP1330468A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
| 07/30/2003 | EP1330467A2 Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| 07/30/2003 | EP1330463A2 Beta-substituted beta-aminoethyl phosphonates |
| 07/30/2003 | EP1330462A1 New process for the production of oxabispidines |
| 07/30/2003 | EP1330461A1 New oxabispidine compound useful in the treatment of cardiac arrhythmias |
| 07/30/2003 | EP1330460A2 Benzoxazinone derivatives, their preparation and use |
| 07/30/2003 | EP1330459A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 07/30/2003 | EP1330456A2 N8,n13 -disubstituted quino 4,3,2-kl]acridinium salts as therapeutic agents |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330453A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 07/30/2003 | EP1330452A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 07/30/2003 | EP1330451A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/30/2003 | EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 07/30/2003 | EP1330447A2 Peptides as met-ap2 inhibitors |
| 07/30/2003 | EP1330444A2 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
| 07/30/2003 | EP1330442A1 Phthalazinone derivatives |
| 07/30/2003 | EP1330441A2 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 07/30/2003 | EP1330439A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 07/30/2003 | EP1330436A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3-3 receptor antagonists |
| 07/30/2003 | EP1330435A1 Crystalline forms of fluvastatin sodium |
| 07/30/2003 | EP1330432A2 Substituted alkanoic acids |
| 07/30/2003 | EP1330430A2 Integrin receptor inhibitors |
| 07/30/2003 | EP1330429A2 Alkynyl amides and their therapeutic applications |
| 07/30/2003 | EP1330428A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 07/30/2003 | EP1330427A1 Crystalline forms of venlafaxine hydrochloride |
| 07/30/2003 | EP1330426A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 07/30/2003 | EP1330425A2 C-nitroso compounds and use thereof |
| 07/30/2003 | EP1330292A2 Radioactive member for use in brachytherapy and method of making |
| 07/30/2003 | EP1330273A1 Coated implantable medical device |
| 07/30/2003 | EP1330271A2 Use of transcription factors for treating inflammation and other diseases |
| 07/30/2003 | EP1330270A2 Sustained release device for treating conditions of the joint |
| 07/30/2003 | EP1330268A1 Targeted therapeutic agents |
| 07/30/2003 | EP1330265A1 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 07/30/2003 | EP1330254A2 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 07/30/2003 | EP1330252A1 In vivo stimulation of angiogenic activity |
| 07/30/2003 | EP1330251A1 Combination therapy for the treatment of estrogen-sensitive disease |
| 07/30/2003 | EP1330249A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 07/30/2003 | EP1330248A2 New treatments for restless legs syndrome |
| 07/30/2003 | EP1330247A1 Use of 1-ebio in the treatment of bipolar disorders |
| 07/30/2003 | EP1330246A1 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 07/30/2003 | EP1330245A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 07/30/2003 | EP1330244A1 Compositions comprising modafinil compounds |
| 07/30/2003 | EP1330243A2 Use of carp inhibitors for the treatment of heart diseases |
| 07/30/2003 | EP1330242A2 Antiproliferative colchicine compositions and uses thereof |
| 07/30/2003 | EP1330241A2 Use of tolterodine to treat asthma |
| 07/30/2003 | EP1330240A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 07/30/2003 | EP1330239A2 Delayed and sustained release formulations and method of use thereof |
| 07/30/2003 | EP1330238A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 07/30/2003 | EP1330235A2 Method and dermatological and/or cosmetic composition for inhibiting the adhesion effect of circulating cells |
| 07/30/2003 | EP1330233A1 Method of treating stroke |
| 07/30/2003 | EP1330226A2 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 07/30/2003 | EP1252141B1 Tosylproline analogs as thymidylate synthase inhibitors |
| 07/30/2003 | EP1233960B1 Polymorphic salt of an anti-migraine drug |
| 07/30/2003 | EP1233763B1 Transdermal therapeutic systems with improved stability and a method for the production thereof |
| 07/30/2003 | EP1187817B1 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same |
| 07/30/2003 | EP1184388B1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
| 07/30/2003 | EP1181288B1 Bicyclic oxazolidinones as antibacterial agent |
| 07/30/2003 | EP1180035A4 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1$g(a), 25-DIHYDROXY VITAMIN D 3? |
| 07/30/2003 | EP1178832B1 Novel medicament compositions, based on tiotropium bromide and salmeterol |
| 07/30/2003 | EP1178787B1 Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof |
| 07/30/2003 | EP1173435B1 Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| 07/30/2003 | EP1171100B1 Solubilized pharmaceutical composition for parenteral administration |
| 07/30/2003 | EP1161234B1 Treatment of pulmonary hypertension by inhalation of benzindene prostaglandins |
| 07/30/2003 | EP1144406B1 Antifungal azole derivatives having a fluorinated vinyl group and process for preparing same |
| 07/30/2003 | EP1135403B1 17beta-acyl-17alpha-propynyl-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 07/30/2003 | EP1112275B1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 07/30/2003 | EP1091936B1 Method for making hydroxy-25-ene-vitamin d compounds |
| 07/30/2003 | EP1082962B1 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b |
| 07/30/2003 | EP1082809B1 Methods of suppressing reference oscillator harmonic interference and related receivers |
| 07/30/2003 | EP1075256B1 Arylhydrocarbon receptor ligand antagonists |
| 07/30/2003 | EP1056442B1 Antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa |
| 07/30/2003 | EP1052989B1 Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction |
| 07/30/2003 | EP1012146B1 Hiv nuclear localization inhibitors |
| 07/30/2003 | EP1011679B1 Use of 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders |
| 07/30/2003 | EP1000078B1 Hybrid anthracyclines from genetically engineered streptomyces galilaeus strains |
| 07/30/2003 | EP0983058B1 Medicinal aerosol products |
| 07/30/2003 | EP0981355B1 Treatment of chronic inflammatory diseases with cm101/gbs toxin |
| 07/30/2003 | EP0966286B1 Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain |